3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
1
CNS
1
Breast
1
Conditions
HER2+ Metastatic Breast Cancer
1
Interventions
Trastuzumab
25
Carboplatin
20
Paclitaxel
19
pertuzumab
18
pyrotinib
17
Cyclophosphamide
17
Capecitabine
16
trastuzumab deruxtecan
15
Docetaxel
15
Radiotherapy
13
Standard of Care
12
Fulvestrant
12
Drug Therapy
12
dalpiciclib
11
Letrozole
11
pembrolizumab
9
Epirubicin
9
sacituzumab govitecan
8
palbociclib
8
exemestane
8
eribulin
8
Anastrozole
8
Injections
7
Doxorubicin
7
130-nm albumin-bound paclitaxel
7
toripalimab
6
abemaciclib
6
Tamoxifen
6
Specimen Handling
6
Neoadjuvant Therapy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
asciminib
×
Breast
×
Clear all
NCT07136428
2026-05-06
ASCENdANT
Duke University
Phase 1/2
Not yet recruiting
42 enrolled